HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Y. Joseph Woo Pavan Atluri Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Woo, Y. J. Articles by Chaudhry, H. W. Search for Related Content PubMed PubMed Citation Articles by Woo, Y. J. Articles by Chaudhry, H. W. Related Collections Molecular biology Myocardial infarction

J Thorac Cardiovasc Surg 2007;133:927-933
© 2007 The American Association for Thoracic Surgery

Cardiopulmonary Support and Physiology

Myocardial regeneration therapy for ischemic cardiomyopathy with cyclin A2

^a Division of Cardiothoracic Surgery, Division of Cardiology, Department of Medicine, Columbia University School of Medicine, New York, New York
^b Department of Surgery, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania; and Division of Cardiology, Department of Medicine, Columbia University School of Medicine, New York, New York.

Read at the Eighty-sixth Annual Meeting of The American Association for Thoracic Surgery, Philadelphia, Pa, April 29-May 3, 2006.

Received for publication April 28, 2006; revisions received June 20, 2006; accepted for publication July 7, 2006.

^_* Address for reprints: Y. Joseph Woo, MD, Department of Surgery, University of Pennsylvania, Silverstein 6, 3400 Spruce St, Philadelphia, PA 19104. (Email: wooy{at}uphs.upenn.edu).

Objective: Heart failure therapies ranging from revascularization to remodeling to replacement are variably effective. Theoretically, endogenous repair via myocardial regeneration would be an ideal therapy. This study examined the ability to initiate regeneration by adenoviral-mediated expression of the cell cycle regulator cyclin A2. Our prior studies have demonstrated robust cyclin A2 transgene expression and marked antiphosphorylated histone H3 activity with this strategy, indicating the induction of cardiomyocyte mitosis.

Methods: Adult male, Lewis rats underwent left anterior descending coronary artery ligation followed by intramyocardial delivery of either cyclin A2 adenoviral vector (n = 8) or empty adeno-null vector as a control (n = 8) into the peri-infarct border zone. In vivo myocardial function was analyzed by echocardiography and invasive left ventricular pressure catheter at 6 weeks, when the animals are traditionally in heart failure. Hearts were explanted for immunoblotting and left ventricular geometric analysis. Cellular proliferation was assessed by proliferating cellular nuclear antigen expression.

Results: Cyclin A2 hearts exhibited improved left ventricular function as compared with controls including enhanced cardiac output (32 ± 3.3 vs 26 ± 5.0 mL/min, P < .05), stroke volume (0.16 ± 0.04 vs 0.11 ± 0.04 mL, P < .05), ejection fraction (72% ± 7.4% vs 46.% ± 8.5%, P < .05), fractional shortening (35% ± 5.4% vs 19% ± 4.3%, P < .002), maximum pressure (72 ± 9.3 vs 61 ± 2.9 mm Hg, P < .05), and end-systolic pressure (67 ± 7.0 vs 55 ± 7.0 mm Hg, P < .05). Enhanced myocardial preservation was demonstrated by enhanced left ventricular border zone wall thickness. Increased myocardial proliferation was evidenced by increased expression of proliferating cell nuclear antigen expression in cyclin A2-treated hearts.

Conclusions: In failing hearts, targeted delivery of cyclin A2 improves hemodynamic function, as measured by echocardiography and pressure catheter analysis, preserves ventricular wall thickness, and may serve as an ideal myocardial regenerative therapy.